| Literature DB >> 29777162 |
Thales A S H Ilha1, Fabio V Comim1,2, Rafaela M Copes1,2, Juliet E Compston3, Melissa O Premaor4,5.
Abstract
The survival of HIV-infected patients has increased with the advent of antiretroviral therapy with the emergence of new comorbidities. Vertebral fracture is a manifestation of reduced bone strength and osteoporosis. This study aims to assess the frequency of spine fractures in HIV-positive men and women aged over 18 years. We performed a systematic review of randomized controlled trials, cohort studies, cross-sectional studies, and case-control studies. Studies that evaluated morphometric and/or clinical vertebral fracture were included. In total 488 studies were found, of which 53 had their full texts evaluated. A total of 85,411 HIV positive individuals were identified in 26 studies. The meta-analysis of the prevalence of vertebral fractures included 12 studies with 10,593 subjects. The prevalence was 11.1% [95% confidence interval (95% CI) 4.5%, 25.0%, I2 98.2% p < 0.00001]. When we evaluated independently studies of clinical vertebral fracture and morphometric vertebral fracture, the prevalence was 3.9% (95% CI 0.9, 15.8, I2 96.4% p < 0.00001) and 20.2% (95% CI 15.7%, 25.6%, I2 69.9% p = 0.003) respectively. HIV-infected individuals had an odds ratio of vertebral fractures of 2.3 (95% CI 1.37, 3.85, I2 98.2% p < 0.00001) when compared with HIV-uninfected patients (n = 9 studies). In conclusion, HIV-positive subjects had a higher risk of vertebral fractures when compared with HIV-negative subjects.Entities:
Mesh:
Year: 2018 PMID: 29777162 PMCID: PMC5959850 DOI: 10.1038/s41598-018-26312-9
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1PRISMA 2009 Flow Diagram of the studies included in the review. The meta-analysis was carried out according to the PRISMA Guidelines[32].
Studies characteristics.
| Author | Year | Study design | Site | Age (years) | Gender (%) | Recruitment time (years of follow-up) | ART(%) | VF ascertainment |
|---|---|---|---|---|---|---|---|---|
| Bedimo[ | 2012 | Cohort | USA | 18–70+ | 98% male | 1988–2009 (21) | 69.4% | ICD |
| Borderi[ | 2014 | Cross-sectional | Italy | 51 (31–67) | 68% male | NA | 86.13% | Semiquantitative/Morphometric |
| Ciullin[ | 2017 | Cross-sectional | Italy | 43 (37–52) | 87.2% male | NA | 93.6% | Semiquantitative/Morphometric |
| Clò[ | 2015 | Cross-sectional | Italy | 47 (24–72) | 64.15% male | NA | — | Lateral spine x-ray |
| Collin[ | 2009 | Cohort | France | 36.2 | 77.2% male | 1997–2009 (7.1) | 100% | — |
| Gallant[ | 2004 | RCT | South America, Europe, USA | 36 | 73.92% male | 48 weeks | 100% | Lateral spine x-ray |
| Gazzola[ | 2015 | Cross-sectional | Italy | 49 (40–51) | 73%male | NA | 70.61% | Semiquantitative/Morphometric |
| Hansen[ | 2012 | Cohort | Denmark | 36.7 (30.5–44.5) | 76% male | 1995–2009 (14) | 78% | ICD |
| Kurita[ | 2014 | Cohort | Japan | 15–81 | 92.8% male | 2005–2010 (5) | 65,9% | — |
| Mazzotta[ | 2015 | Cross-sectional | Italy | 44.2 ± 10 | 70.6% male | NA | 79.7% | Self-reported |
| Pepe[ | 2012 | Cross-sectional | Italy | 48.6 (40–69) | 100% male | NA | 100% | Semiquantitative |
| Porcelli[ | 2014 | Cross-sectional | Italy | 51 (36–75) | 71% male | NA | 100% | Semiquantitative/Morphometric |
| Prieto-Alhambra[ | 2014 | Case-control | Denmark | 43.4 ± 27.4 | 51.8% female | 2009 (1) | — | ICD |
| Sharma[ | 2015 | Cohort | USA | 40 (34–46) | 100% female | 2002–2013 (10) | 63% | Self-reported |
| Short[ | 2014 | Cross-sectional | UK | 45 (38–51) | 100% male | NA | 78% | Self-reported |
| Torti[ | 2012 | Cross-sectional | Italy | 53 (42–71) | 100% male | NA | 78.12% | Semiquantitative/Morphometric |
| Triant[ | 2008 | Case- control | USA | 20–79 | 65.16% male | 1996–2008 | — | ICD |
| Womack*,[ | 2011/2013 | Cohort | USA | 53 (48–61) | 100% male | 1997–2009 (6 ± 3.9) | 75% | ICD |
| Yang[ | 2012 | Cohort | Taiwan | <20–>60 | 76.9–90.1% male | 2005–2008 | — | ICD |
| Yin[ | 2012 | Cohort | USA | 39 (33–45) | 83% male | (5) | 99.69% | Self-reported |
| Yin[ | 2010 | Cross-sectional | USA | 55.9 ± 0.7 | 100% female | 2002–2007 | 79.34% | Semiquantitative |
| Yong[ | 2011 | Case-control | Australia | 49.8 | 88.54% male | 1998–2009 (10.5) | 80.32% | ICD/Victorian HIV Database |
| Young[ | 2011 | Cohort | USA | 40 (34–46) | 79% male | 2000–2008 | 72.7% | Self-reported /HOPS electronic databases |
—=information not given; NA = not assessed; RCT = Randomized Clinical Trial; ICD = International Code Diseases; *The data were extracted from two different articles with the same cohort.
Figure 2Forest plot of the prevalence of vertebral fractures in HIV-positive subjects. The proportions were pooled applying LOGIT transformation, using random effects model, with DerSimonian and Laird as variance estimator. Results were presented as a pooled prevalence, 95% confidence intervals. The p-value for subgroup analysis on the differences of the prevalence by type of fracture assessment is 0.021.
Details of Incidence Vertebral Fracture by Cohort.
| Cohort | Persons/Years | Incident Vertebral Fracture* | 95% - CI |
|---|---|---|---|
| Bedimo | 305237 | 0.4 | 0.3–0.5 |
| Collin | 6380 | 0.5 | 0.1–1.4 |
| Gallant | 1533 | 0.7 | 0.0–3.6 |
| Hansen | 29348 | 0.6 | 0.4–1.0 |
| Kurita | 2805 | 0.7 | 0.1–2.6 |
| Sharma | 22520 | 1.2 | 0.8–1.7 |
| Yang | 12898 | 0.5 | 0.2–1.0 |
| Yin | 23200 | 0.3 | 0.1–0.6 |
| Yong | 25452 | 0.7 | 0.4 -. 1.1 |
| Young | 1216 | 14.8 | 8.8–23.3 |
|
|
|
*Per 1.000 persons/years; CI = confidence interval.
Figure 3Forest plot of the odds ratio of vertebral fractures in HIV-positive subjects. The pooled odds ratio was estimated using random effects model, with DerSimonian and Laird as variance estimator. Results were presented as a pooled odds ratio, 95% confidence intervals. The p-value for subgroup analysis on the differences of the prevalence by type of fracture assessment is 0.211.
Meta-regression analysis of the prevalence rate covariates.
| Subgroups | No of studies | RP | Summary effects | p Value | Heterogeneity | ||
|---|---|---|---|---|---|---|---|
| I², % | p Value | ||||||
| Meta-regression for age | Age (years) | 12 | 0.07 | −0.18, 0.34 | 0.553 | 98.31 | <0.0001 |
| Meta-regression for gender | Male | 12 | −0.01 | −0.06, 0.05 | 0.846 | 97.70 | <0.0001 |
| Meta-regression for study location | Italy* | 12 | −1.02 | −1.36, −0.67 | <0.0001 | 79.22 | <0.0001 |
| Meta-regression for sample size | n | 12 | −0.0003 | −0.0005, −0.0002 | <0.0001 | 82.06 | <0.0001 |
| Meta-regression for study year | Year | 12 | 0.22 | −0.06, 0.50 | 0.192 | 95.06 | <0.0001 |
| Meta-regression for study quality | Moderate quality** | 12 | −1.74 | −2.95, −0.54 | 0.0045 | 92.81 | <0.0001 |
Main results of the meta-regression. C-C = case control studies; C-S = cross-section studies; VF = vertebral fractures; RP = prevalence ratio;
*when compared with UK; **when compared with high quality.